%0 Journal Article
%A Certa, Franziska
%A Horn, Peter A
%A Keyl, Julius
%A Mende, Bastian
%A Lueong, Smiths
%A Hilser, Thomas
%A Theurer, Sarah
%A Virchow, Isabel
%A Zaun, Yasmin
%A Pogorzelski, Michael
%A Metzenmacher, Martin
%A Kalkavan, Halime
%A Kasper, Stefan
%A Schuler, Martin
%A Wiesweg, Marcel
%A Zaun, Gregor
%T ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
%J Thoracic cancer
%V 16
%N 6
%@ 1759-7706
%C Hoboken, NJ ˜[u.a.]œ
%I Wiley-Blackwell
%M DKFZ-2025-00596
%P e70037
%D 2025
%X In patients with metastatic non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression, there is still a lack of biomarkers to identify patients with maximum benefit from first-line treatment with checkpoint inhibitor therapy (CIT) alone. This work examines the impact of different ABO blood groups (BG) on the response to CIT monotherapy.Retrospective analysis of patients with stage IV NSCLC and high PD-L1 expression (tumor proportional score/TPS ≥ 50
%K Humans
%K Antibodies, Monoclonal, Humanized: therapeutic use
%K Carcinoma, Non-Small-Cell Lung: drug therapy
%K Carcinoma, Non-Small-Cell Lung: mortality
%K Carcinoma, Non-Small-Cell Lung: pathology
%K Lung Neoplasms: drug therapy
%K Lung Neoplasms: mortality
%K Lung Neoplasms: pathology
%K Male
%K Female
%K ABO Blood-Group System
%K Retrospective Studies
%K Middle Aged
%K Aged
%K Adult
%K Aged, 80 and over
%K Prognosis
%K Antineoplastic Agents, Immunological: therapeutic use
%K Survival Rate
%K blood group (Other)
%K checkpoint inhibitor (Other)
%K non‐small cell lung cancer (Other)
%K predictive biomarkers (Other)
%K pembrolizumab (NLM Chemicals)
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K ABO Blood-Group System (NLM Chemicals)
%K Antineoplastic Agents, Immunological (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40114329
%2 pmc:PMC11925720
%R 10.1111/1759-7714.70037
%U https://inrepo02.dkfz.de/record/300096